

NOVO NORDISK A S
Form 6-K
December 04, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

December 4, 2015

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the EU for the treatment of type 1 and 2 diabetes

Bagsværd, Denmark, 4 December 2015 - Novo Nordisk today announced the submission to the European Medicines Agency of the Marketing Authorisation Application (MAA) for the approval of faster-acting insulin aspart. Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes.

Novo Nordisk expects to file the new drug application for faster-acting insulin aspart to the US Food and Drug Administration before year-end 2015.

The filing of faster-acting insulin aspart is based on the results from the 'onset' clinical trial programme which involved around 2,100 people with type 1 and 2 diabetes. In the onset programme, people treated with faster-acting insulin aspart achieved improvements in postprandial control versus NovoRapid® and an HbA_{1c} reduction on par with NovoRapid®. For people with type 1 diabetes, faster-acting insulin aspart results from the double-blinded onset 1 trial

showed statistically significantly greater HbA_{1c} reduction when dosed at mealtime or similar HbA_{1c} reduction when dosed 20 minutes after a meal compared to NovoRapid®. Across the onset trials, faster-acting insulin aspart had a safe and well tolerated profile, with the most common adverse event being hypoglycaemia, similar to the levels observed with NovoRapid®.

"With the regulatory filing of faster-acting insulin aspart, we take yet another step in helping people with diabetes improve their blood glucose control around meals," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "Onset 1 shows that faster-acting insulin aspart has the potential to offer improved postprandial glucose and either an additional reduction of HbA_{1c} or added flexibility compared with NovoRapid®."

Novo Nordisk intends to make faster-acting insulin aspart available in the prefilled delivery device FlexTouch®.

About faster-acting insulin aspart

Faster-acting insulin aspart is a mealtime insulin for the control of postprandial glucose excursions in type 1 and type 2 diabetes as well as in pump treatment. Faster-acting insulin aspart is insulin aspart (NovoRapid®) in a new formulation in which two new excipients have been added to ensure early and fast absorption.

About the onset clinical programme

The onset programme is a phase 3 clinical programme with faster-acting insulin aspart consisting of four trials encompassing more than 2,100 people with type 1 and type 2 diabetes.

The onset 1 trial (1,143 people randomised) - a 26+26-week randomised, double-blinded, basal-bolus, treat-to-target trial investigating faster-acting insulin aspart compared to NovoRapid®, both in combination with Levemir® in adults with type 1 diabetes. The results were reported in March and October 2015.

The onset 2 trial (689 people randomised) - a 26-week randomised, double-blinded, basal-bolus, treat-to-target trial investigating faster-acting insulin aspart compared to NovoRapid®, both in combination with insulin glargine in adults with type 2 diabetes. The results were reported in March 2015.

The onset 3 trial (236 people randomised) - an 18-week randomised, open-label, basal bolus vs basal trial confirming superiority (in terms of HbA_{1c}) of mealtime faster-acting insulin aspart in a full basal-bolus regimen versus basal insulin therapy, both in combination with metformin. The results were reported in January 2015.

The onset 4 trial (37 people randomised) - a six-week randomised, double-blinded, parallel-group trial confirming pump compatibility and safety of faster-acting insulin aspart and NovoRapid® in type 1 diabetes. The results were reported in August 2014.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

For further information

Media:

Mike Rulis +45 3079 3573 mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com

Investors:

Peter Hugrefte Ankersen +45 3079 4303 phak@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje +45 3079 8519 kpvj@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Novo Nordisk A/S Novo Allé Telephone: Internet:
Investor Relations 2880 Bagsværd +45 4444 8888 www.novonordisk.com
Denmark CVR no:
24 25 67 90

Company announcement No 75 / 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: December 4, 2015

Lars Rebien Sørensen,

Chief Executive Officer